Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced the engagement of The Trout Group LLC, a leading New York-based investor relations and strategic advisory firm. The Trout Group will work with Raptor to facilitate the Company's exposure to the international capital markets and coordinate their communications with investors worldwide. With extensive institutional investor relationships in the United States and Europe, The Trout Group provides strategic advisory and investor relations services exclusively to Life Sciences companies.
"Over the last 4 years, Raptor has grown from an angel funded start-up with exciting preclinical programs to a later-stage NASDAQ-listed biotechnology company with what we believe is a solid clinical pipeline. The Company's lead clinical program, DR Cysteamine for the potential treatment of cystinosis, will soon enter its final clinical trial and may be ready for commercial launch in 2011," stated Christopher M. Starr, Ph.D., Raptor's chief executive officer. "With our existing investor base spread throughout Europe, Canada, Australia and the U.S., the global capabilities of The Trout Group will enable us to consolidate our investor communication and outreach. Their experience in emerging life science companies and orphan product clinical programs is a perfect fit with our current needs and will be a tremendous asset to us as we complete the final clinical phase of our cystinosis program and prepare for a potential commercial launch next year."
FORT-2 trial shows promising results for bladder cancer immunotherapy combination